Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2010. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions and does not contain financial statements or performance metrics.
Material Changes
The filing details changes in shareholdings for five individuals resulting from the reinvestment of dividends on August 4, 2010. The shares were purchased at a price of £11.31 per ordinary share within an Individual Savings Account (ISA). The specific changes are:
- Mr A P Witty: 17 shares
- Mr J S Heslop: 8 shares
- Mr S M Bicknell: 63 shares
- Mr E J Gray: 7 shares
- Mr D S Redfern: 7 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director share transactions.
Investor Verification Points
- Verify the share price of £11.31 per ordinary share on August 4, 2010.
- Confirm the total number of shares acquired by the named directors through dividend reinvestment.
- Check subsequent filings for any further changes in director shareholdings.